JP2021522839A5 - - Google Patents

Info

Publication number
JP2021522839A5
JP2021522839A5 JP2020564137A JP2020564137A JP2021522839A5 JP 2021522839 A5 JP2021522839 A5 JP 2021522839A5 JP 2020564137 A JP2020564137 A JP 2020564137A JP 2020564137 A JP2020564137 A JP 2020564137A JP 2021522839 A5 JP2021522839 A5 JP 2021522839A5
Authority
JP
Japan
Prior art keywords
cells
composition
approximately
cell
subset
Prior art date
Application number
JP2020564137A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522839A (ja
JPWO2019222293A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/032318 external-priority patent/WO2019222293A1/en
Publication of JP2021522839A publication Critical patent/JP2021522839A/ja
Publication of JP2021522839A5 publication Critical patent/JP2021522839A5/ja
Publication of JPWO2019222293A5 publication Critical patent/JPWO2019222293A5/ja
Priority to JP2024067406A priority Critical patent/JP2024096956A/ja
Pending legal-status Critical Current

Links

JP2020564137A 2018-05-14 2019-05-14 増強された抗体指向性免疫応答を有するヒトナチュラルキラー細胞のサブセット Pending JP2021522839A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024067406A JP2024096956A (ja) 2018-05-14 2024-04-18 増強された抗体指向性免疫応答を有するヒトナチュラルキラー細胞のサブセット

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671358P 2018-05-14 2018-05-14
US62/671,358 2018-05-14
PCT/US2019/032318 WO2019222293A1 (en) 2018-05-14 2019-05-14 Subsets of human natural killer cells with enhanced antibody-directed immune responses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024067406A Division JP2024096956A (ja) 2018-05-14 2024-04-18 増強された抗体指向性免疫応答を有するヒトナチュラルキラー細胞のサブセット

Publications (3)

Publication Number Publication Date
JP2021522839A JP2021522839A (ja) 2021-09-02
JP2021522839A5 true JP2021522839A5 (https=) 2022-05-19
JPWO2019222293A5 JPWO2019222293A5 (https=) 2022-05-19

Family

ID=68541145

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020564137A Pending JP2021522839A (ja) 2018-05-14 2019-05-14 増強された抗体指向性免疫応答を有するヒトナチュラルキラー細胞のサブセット
JP2024067406A Pending JP2024096956A (ja) 2018-05-14 2024-04-18 増強された抗体指向性免疫応答を有するヒトナチュラルキラー細胞のサブセット

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024067406A Pending JP2024096956A (ja) 2018-05-14 2024-04-18 増強された抗体指向性免疫応答を有するヒトナチュラルキラー細胞のサブセット

Country Status (10)

Country Link
US (1) US20210187025A1 (https=)
EP (2) EP4474391A3 (https=)
JP (2) JP2021522839A (https=)
CN (1) CN112839666A (https=)
AU (1) AU2019271146A1 (https=)
CA (1) CA3099806A1 (https=)
DK (1) DK3793573T3 (https=)
ES (1) ES2993360T3 (https=)
PT (1) PT3793573T (https=)
WO (1) WO2019222293A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10066207B2 (en) 2012-04-18 2018-09-04 Board Of Trustees Of Michigan State University Natural killer cells with enhanced immune response
CN110546265A (zh) 2017-02-09 2019-12-06 因达普塔治疗公司 工程化自然杀伤(nk)细胞及其组合物和方法
US12410402B2 (en) 2018-11-21 2025-09-09 Indapta Therapeutics, Inc. Methods for expansion of natural killer (NK) cell subset and related compositions and methods
KR20230088306A (ko) * 2020-04-22 2023-06-19 인답타 세라뷰틱스 인코포레이티드 자연 살해(ｎｋ) 세포 조성물 및 이를 생성하는 방법
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
AU2021392032A1 (en) 2020-12-03 2023-06-22 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
AU2022254689A1 (en) * 2021-04-08 2023-11-16 Artiva Biotherapeutics, Inc. Treatment of cancer with nk cells and a her2 targeted antibody
JP2024515169A (ja) * 2021-04-08 2024-04-05 アルティヴァ バイオセラピューティクス インコーポレイテッド Ｎｋ細胞およびｃｄ２０標的抗体を用いた癌治療
AU2022253256A1 (en) * 2021-04-08 2023-11-16 Artiva Biotherapeutics, Inc. Treatment of cancer with nk cells and a cd38-targeted antibody
JP2024513958A (ja) * 2021-04-08 2024-03-27 アルティヴァ バイオセラピューティクス インコーポレイテッド Ｎｋ細胞およびｅｇｆｒ標的抗体を用いた癌治療
CN117715647A (zh) * 2021-04-08 2024-03-15 埃迪瓦生物治疗公司 用nk细胞和cd38靶向抗体治疗癌症
WO2022226130A1 (en) * 2021-04-21 2022-10-27 Indapta Therapeutics, Inc. Methods of treatment and dosing of natural killer cell compositions
CN115369086B (zh) * 2022-02-22 2023-05-12 北京景达生物科技有限公司 一种nk细胞扩大培养的培养方案
CN116679065B (zh) * 2023-07-31 2023-11-14 北京大学人民医院 检测试剂的应用、多发性骨髓瘤治疗预后预测方法及产品

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6016891A (en) 1998-08-10 2000-01-25 Sava; John G. Tree stand harness system
WO2005118854A1 (en) * 2004-06-01 2005-12-15 Centre Hospitalier Regional Et Universitaire De Tours Fcgr3a gebotype and methods for evaluating treatment response to non-depleting antibodies
DE602005016683D1 (de) * 2004-07-10 2009-10-29 Fox Chase Cancer Ct Genetisch modifizierte, menschliche, natürliche killerzellenlinien:
JP5282040B2 (ja) * 2007-09-28 2013-09-04 オリンパス株式会社 Ｆｃ受容体遺伝子導入ＮＫ細胞を用いた抗体依存性細胞傷害のアッセイ方法
WO2012061814A1 (en) 2010-11-05 2012-05-10 Transgenomic, Inc. Pcr primers and methods for rapid and specific genotyping
US10066207B2 (en) * 2012-04-18 2018-09-04 Board Of Trustees Of Michigan State University Natural killer cells with enhanced immune response
US10813952B2 (en) * 2014-11-14 2020-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors
CN110546265A (zh) * 2017-02-09 2019-12-06 因达普塔治疗公司 工程化自然杀伤(nk)细胞及其组合物和方法

Similar Documents

Publication Publication Date Title
JP2021522839A5 (https=)
US12466871B2 (en) Fusion protein for use in the treatment of HVG disease
Jin et al. CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers
Wu et al. Clonal expansion and compartmentalized maintenance of rhesus macaque NK cell subsets
JP2022515290A (ja) 改変ｔ細胞、その調製方法および使用
JP2019523001A5 (https=)
JP7584437B2 (ja) 抗ｂｃｍａ ｃａｒ ｔ細胞の製造
US20220289849A1 (en) Car for use in the treatment of hvg disease
AU2018342245A1 (en) Methods of isolating T cells having antigenic specificity for a p53 cancer-specific mutation
JP2016509840A5 (https=)
JP2020507349A5 (https=)
JPWO2019222293A5 (https=)
CN106434552B (zh) 新型nkt样细胞亚群及其治疗肿瘤的用途
WO2020210365A1 (en) Dnmt3a knock-out and stat5 activated genetically engineered t-cells
CN107002036A (zh) 用于建立具有编码抗原特异性t细胞受体的基因的多能性干细胞的方法
CN117355327A (zh) 表达用于下调mhc i类和ii类表达的嵌入人工微rna中的shrna的car nkt
Song et al. Manufacture of CD22 CAR T cells following positive versus negative selection results in distinct cytokine secretion profiles and γδ T cell output
CN115835873A (zh) 用于产生表达重组受体的供体分批细胞的方法
US20260034218A1 (en) Alleviating graft versus host disease using engineered inkt cells
JP2006340698A (ja) Ｎｋ細胞活性化方法、これを用いたｎｋ細胞増殖方法及び細胞製造方法並びにｎｋ細胞を含む単核球
Boje et al. A Novel Natural Killer Cell Expansion Technology for the Development of Cellular Immunotherapies
Cornel et al. Best of two worlds: Engineering NKT-cells to generate an alternative adaptive cell therapy strategy against neuroblastoma
Kochs et al. Reprogramming Antitumor Immunity: NK Cell Strategies to Navigate the Immunosuppressive Tumor Microenvironment
KR20260026056A (ko) 시험관 내에서 유래된 t 세포 모집단, 이의 생성 방법, 및 사용 방법
Giannakopoulou et al. ang, WW, Li